Since bexarotene suppresses CCL22/CCR4‐related chemotaxis,3, 4 bexarotene might modulate the profiles of TILs to induce an anti‐CTCL immune response in CTCL patients. The gene discussed is CCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.